Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
The New England journal of medicine（2023）
摘要
At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall survival than standard care. (Funded by Kite; ZUMA-7 ClinicalTrials.gov number, NCT03391466.).
更多查看译文
关键词
axicabtagene ciloleucel,lymphoma,b-cell
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要